Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-arm Study of Nirogacestat in Japanese Adults With Progressing Desmoid Tumors/Aggressive Fibromatosis
jRCT2031250269Phase 2Active, not recruiting
- Sponsor
- SpringWorks Therapeutics
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nirogacestat in aggressive fibromatosis (AF), sponsored by SpringWorks Therapeutics. Primary endpoint: Objective response rate by independent central review (RECIST v1.1). Started Aug 2025; status: active, not recruiting.
02
Drugs
nirogacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on jRCT2031250269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250269.